How to Get Vyleesi (Bremelanotide) in Kansas

What Is Vyleesi and Why Does HSDD Affect So Many Kansas Women?

Vyleesi is the brand name for bremelanotide, an FDA-approved melanocortin receptor agonist that works on the central nervous system to increase sexual desire. The FDA granted approval in June 2019 based on the RECONNECT trial program, making it one of only two FDA-approved pharmacologic treatments for HSDD in premenopausal women. [1]

HSDD is defined as persistent low sexual desire that causes personal distress. Epidemiological surveys estimate that roughly 8 to 10 percent of U.S. women aged 18 to 44 meet diagnostic criteria for distressing low desire, [2] which translates to hundreds of thousands of women in Kansas across the Wichita, Kansas City metro, Topeka, and Lawrence areas who may benefit from treatment.

Bremelanotide differs from flibanserin (Addyi), the other FDA-approved HSDD drug, in one key way. Flibanserin is taken nightly and takes four to eight weeks to show benefit. Bremelanotide is injected on demand, 45 minutes before sexual activity, with no daily dosing schedule required. [3] That distinction matters clinically for women who prefer not to commit to a daily medication.

The RECONNECT trials enrolled 1,267 premenopausal women with HSDD across two randomized, double-blind, placebo-controlled studies. Women assigned to bremelanotide 1.75 mg reported a statistically significant increase in satisfying sexual events and a significant decrease in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score compared with placebo (P<0.001 for both co-primary endpoints). [1] The most common adverse effect was transient nausea, reported by 40 percent of bremelanotide-treated participants versus 1 percent of placebo, typically resolving within 12 hours. [1]

The Kansas Legal Framework for Prescribing and Dispensing Vyleesi

Kansas permits telehealth prescribing of Schedule-uncontrolled medications, and bremelanotide is not a controlled substance. That means a clinician licensed in Kansas can write a valid bremelanotide prescription after a synchronous audio-video encounter without a prior in-person visit. [4]

The Kansas Telemedicine Act (K.S.A. 65-6769) requires that a valid patient-prescriber relationship be established before a prescription is issued. A secure video visit satisfies this requirement. [4] Audio-only encounters are permissible only when video technology is unavailable, so most telehealth platforms default to video for HSDD consults.

Nurse practitioners and physician assistants with full prescriptive authority under Kansas law can prescribe bremelanotide. Kansas NPs have independent prescriptive authority after completing required clinical hours, so you do not need to see an MD specifically. [5]

503A compounding pharmacies licensed by the Kansas Board of Pharmacy are authorized to compound bremelanotide for individual patient prescriptions. Compounded bremelanotide is not FDA-approved and may differ in concentration, vehicle, or excipients compared with the brand Vyleesi auto-injector. Patients should discuss the trade-offs with their prescriber before choosing a compounded formulation.

Step-by-Step: Getting a Vyleesi Prescription in Kansas

Step 1. Choose a Prescriber or Telehealth Platform

You have three practical routes:

A Kansas-based OB/GYN, family medicine physician, or women's health NP. Many practices in Wichita (e.g., Via Christi Women's Health), Kansas City metro (Overland Park), and Topeka now offer HSDD assessments. Call ahead to confirm the practice is familiar with bremelanotide, because some primary care offices still route HSDD concerns to specialists.

A national telehealth platform registered in Kansas. Several platforms, including HealthRX, offer synchronous video visits specifically for women's sexual health and are registered to prescribe in Kansas. A visit typically runs 20 to 30 minutes.

A sexual medicine or psychiatry specialist. If your HSDD is complicated by relationship distress, past trauma, or comorbid depression, a certified sexual medicine specialist or psychiatrist may provide a more complete evaluation alongside any pharmacologic treatment.

Step 2. Complete Your Intake and Medical History

Before your video visit, you will typically fill out a digital intake form covering:

• Duration and description of low desire symptoms
• Relationship status and partner-related context
• Current medications (SSRIs, combined oral contraceptives, and antihypertensives are common HSDD contributors)
• Cardiovascular history (relevant because bremelanotide can transiently increase blood pressure by 6 mmHg systolic for up to 12 hours after dosing) [3]
• Prior treatment with flibanserin

No fasting labs are required before the first bremelanotide dose. Some clinicians order a basic metabolic panel or thyroid panel if an organic cause of low libido is suspected, but this is not a universal protocol requirement.

Step 3. The Telehealth Visit

Your clinician will review your intake form, ask clarifying questions, and apply a structured diagnostic approach. The most widely used clinical tool is the FSFI (Female Sexual Function Index), a 19-item validated questionnaire. A total FSFI score below 26.55 suggests female sexual dysfunction. [6]

The clinician will also screen for HSDD-mimicking conditions: hypothyroidism, hyperprolactinemia, relationship conflict, or medication-induced low desire. If an organic cause is identified, it will be addressed first or alongside pharmacotherapy.

The HealthRX clinical team uses a three-question rapid screen before prescribing bremelanotide: (1) Is the desire deficit the primary complaint rather than arousal or orgasm difficulty? (2) Is the deficit causing personal distress on at least a moderate level by the FSDS-DAO question 13? (3) Are there no absolute contraindications, specifically known cardiovascular disease or concurrent use of a naltrexone-containing product? A "yes, yes, no" response pattern supports proceeding directly to a bremelanotide trial.

Step 4. Prescription Issuance and Pharmacy Selection

Once the clinician confirms that bremelanotide is appropriate, the prescription is sent electronically. You have several pharmacy options:

Brand Vyleesi through a retail or mail-order pharmacy. Major chains including Walgreens, CVS, and mail-order pharmacies like Express Scripts can fill a Vyleesi prescription in Kansas. A 4-dose kit (4 auto-injectors) has a list price near $1,050, but manufacturer savings cards can reduce out-of-pocket cost to as low as $99 per kit for commercially insured patients meeting eligibility criteria. [7]

503A compounding pharmacy. Licensed Kansas compounding pharmacies can prepare bremelanotide as a subcutaneous injection at a provider-specified dose. Compounded versions are typically less expensive than brand Vyleesi, often $150 to $300 for a multi-dose supply. Confirm the pharmacy holds a current Kansas Board of Pharmacy compounding license before dispensing.

Specialty pharmacy programs. Walgreens Specialty and AllianceRx Walgreens Prime have dedicated programs for Vyleesi fulfillment with patient support services including injection training.

Step 5. Insurance and Prior Authorization

Kansas Medicaid does not cover Vyleesi for HSDD. Commercial insurer coverage is inconsistent. A 2023 review by the Academy of Managed Care Pharmacy found that fewer than 40 percent of commercial formularies listed flibanserin or bremelanotide in any tier. [8]

If your insurer requires prior authorization (PA), your prescriber will need to document:

• A formal HSDD diagnosis code (ICD-10 N52.0 is not appropriate; F52.0, Hypoactive Sexual Desire Disorder, is the correct code)
• Distress criterion met per validated scale
• Absence of a reversible organic cause
• For some payers, a trial of behavioral or psychological intervention (though the evidence requirement for this varies by plan)

Dr. Sharon Parish, a sexual medicine specialist at Weill Cornell Medicine, has noted in published commentary that "the prior authorization process for both approved HSDD medications remains a significant access barrier because it imposes documentation burdens that exceed those required for many other psychiatric medications." [9] Building that documentation into the initial telehealth visit reduces the back-and-forth with insurers considerably.

How to Use Bremelanotide Correctly

The standard dose is 1.75 mg injected subcutaneously into the abdomen or thigh approximately 45 minutes before anticipated sexual activity. [3] Do not use more than one dose within 24 hours. The FDA label recommends against using more than one dose per 24-hour window because the transient blood pressure rise can be additive with repeat dosing. [3]

Self-injection technique matters. The auto-injector delivers the dose automatically when pressed firmly against the skin; the needle does not need to be manually inserted. Rotation of injection sites prevents local reactions. The most common injection-site reactions in RECONNECT were bruising and localized pain, each occurring in roughly 13 percent of participants. [1]

Contraindications to know:

• Known cardiovascular disease or uncontrolled hypertension. The labeling warns that bremelanotide causes a mean 6 mmHg increase in systolic blood pressure and a mean 1.3 mmHg decrease in diastolic, peaking about 4 hours post-injection and resolving within 12 hours in most patients. [3]
• Concurrent use of naltrexone (including naltrexone-bupropion, i.e., Contrave). Bremelanotide is a melanocortin receptor agonist and its efficacy may be attenuated by opioid antagonism. Nausea risk also increases.
• Pregnancy. Bremelanotide is FDA Pregnancy Category, and animal data showed fetal harm at doses approximating human exposure; use should be discontinued if pregnancy is confirmed. [3]

Hyperpigmentation (focal darkening of skin, gums, or breasts) was reported in 1 percent of women using bremelanotide for one year in an open-label extension study. [1] Patients with darker skin tones or those who developed hyperpigmentation on hormonal contraceptives should be counseled about this possibility before starting.

Telehealth Platforms Serving Kansas for Vyleesi Prescriptions

Several telehealth services are licensed to prescribe in Kansas and specifically offer women's sexual health services. When evaluating a platform, ask these five questions:

1. Is the prescribing clinician licensed in Kansas, not just a neighboring state?
2. Does the platform offer synchronous video (not just asynchronous questionnaire) to satisfy the Kansas patient-prescriber relationship requirement?
3. Can the clinician send the prescription to a Kansas pharmacy of your choosing?
4. Does the platform assist with prior authorization paperwork if insurance coverage is attempted?
5. Is follow-up included if nausea is intolerable or if the drug is not producing the desired response after 2 to 4 uses?

HealthRX offers HSDD telehealth visits in Kansas with licensed clinicians, e-prescribing to any in-state or mail-order pharmacy, and an optional 4-week follow-up message thread for dose adjustment questions.

What Happens If Vyleesi Does Not Work?

Roughly 20 to 25 percent of women in RECONNECT did not achieve the threshold for a meaningful improvement in satisfying sexual events. [1] Non-response after four to six uses warrants a clinical reassessment. Common reasons for suboptimal response include:

• Relationship distress that pharmacotherapy alone cannot address. The ISSWSH (International Society for the Study of Women's Sexual Health) 2019 Process of Care guidelines recommend that psychological or couples-based interventions be offered alongside or instead of pharmacotherapy when relationship factors are prominent. [10]
• Ongoing SSRI or SNRI use. Antidepressant-induced sexual dysfunction is a separate diagnosis (F52.0 with a medication-contributing note) and may respond better to switching to bupropion or adding buspirone than to bremelanotide. [10]
• Undiagnosed hypoactive desire related to peri-menopausal estrogen decline. Bremelanotide is labeled for premenopausal women only; perimenopausal women with genitourinary syndrome of menopause alongside HSDD may see better outcomes with systemic or local estrogen.
• Inadequate timing of the dose. Some women inject 30 minutes before activity but Vyleesi's Tmax is approximately 1 hour post-injection. [3] Adjusting the timing to 60 minutes before activity sometimes improves the perceived effect.

The alternative FDA-approved option is flibanserin (Addyi) 100 mg taken nightly at bedtime. The DAISY and VIOLET trials (combined N approximately 5,500) showed flibanserin increased satisfying sexual events by about 0.5 per month above placebo at 24 weeks. [11] Flibanserin carries a black-box warning for hypotension and syncope with alcohol and moderate-to-strong CYP3A4 inhibitors, making the interaction profile more complex than bremelanotide's for many patients.

Kansas-Specific Considerations: Insurance, Medicaid, and Pharmacy Availability

Kansas Medicaid (KanCare) covers GLP-1 medications only for type 2 diabetes management and does not list bremelanotide or flibanserin on any KanCare formulary tier. [12] Women with KanCare coverage will need to pay out of pocket or use the manufacturer's patient assistance program.

The Palatin Technologies / AMAG patient assistance program (Vyleesi Connect) provides the medication at no cost to uninsured or underinsured patients who meet income criteria (generally below 400 percent of the federal poverty level). Applications can be started through the prescribing clinician's office.

Commercial payers operating in Kansas such as Blue Cross Blue Shield of Kansas, Aetna Kansas, and Cigna Healthcare of Kansas may cover Vyleesi with a step-edit requiring documented failure of non-pharmacologic treatment or documentation of distress per validated scale. Always confirm your plan's specific formulary before your telehealth visit, because coverage tiers change January 1 of each plan year.

Kansas has 22 licensed 503A compounding pharmacies capable of compounding sterile injectables, though not all of them stock bremelanotide API. Asking the prescriber to include the specific active pharmaceutical ingredient on the referral note helps the pharmacy source material quickly. A typical turnaround from a Kansas 503A compounder is 5 to 10 business days for a sterile injectable preparation.

Storing and Traveling With Vyleesi in Kansas

Brand Vyleesi auto-injectors should be stored at room temperature between 68°F and 77°F (20°C and 25°C), with excursions permitted to 59°F to 86°F. [3] They do not require refrigeration, which simplifies travel. Kansas summers can push car interior temperatures well above 86°F, so do not leave auto-injectors in a parked vehicle during June through August.

Compounded bremelanotide vials may require refrigeration at 36°F to 46°F depending on the compounding pharmacy's formulation. Confirm storage requirements with your pharmacy at the time of dispensing.

When traveling outside Kansas, the prescription label on the original packaging serves as documentation for TSA screening and for filling at an out-of-state pharmacy if needed.